ChromaDex (NASDAQ:CDXC) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of ChromaDex (NASDAQ:CDXC) from a strong-buy rating to a buy rating in a research note released on Friday.

Other equities analysts also recently issued research reports about the company. Roth Mkm upped their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. HC Wainwright upped their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, November 4th.

ChromaDex Stock Performance

NASDAQ:CDXC opened at $5.51 on Friday. The stock’s fifty day moving average is $6.29 and its 200 day moving average is $4.24. ChromaDex has a fifty-two week low of $1.36 and a fifty-two week high of $7.97. The firm has a market capitalization of $420.87 million, a PE ratio of 551.55 and a beta of 2.15.

ChromaDex (NASDAQ:CDXC) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The company had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same quarter in the prior year, the company posted ($0.01) EPS. Equities analysts forecast that ChromaDex will post 0.04 EPS for the current year.

Insider Transactions at ChromaDex

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the transaction, the director now owns 244,179 shares of the company’s stock, valued at approximately $1,511,468.01. This represents a 13.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 9.64% of the company’s stock.

Hedge Funds Weigh In On ChromaDex

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. grew its position in shares of ChromaDex by 11.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock worth $1,211,000 after buying an additional 33,150 shares in the last quarter. Franklin Resources Inc. bought a new stake in ChromaDex during the third quarter valued at about $68,000. Barclays PLC boosted its position in ChromaDex by 322.1% during the third quarter. Barclays PLC now owns 70,072 shares of the company’s stock valued at $256,000 after purchasing an additional 53,472 shares in the last quarter. Geode Capital Management LLC boosted its position in ChromaDex by 1.6% during the third quarter. Geode Capital Management LLC now owns 1,149,592 shares of the company’s stock valued at $4,197,000 after purchasing an additional 17,963 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in ChromaDex by 100.3% during the third quarter. Jane Street Group LLC now owns 45,712 shares of the company’s stock valued at $167,000 after purchasing an additional 22,889 shares in the last quarter. Institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.